SMMT Company Profile and Key Details

SMMT has shown mixed momentum, gaining 7.66% over the past week and -15.52% over the past quarter, though year-to-date performance is up 7.66%. Short-term trend indicators are mixed aligned (SMA20 9.72%, SMA50 9.86%, SMA200 -9.75%). The stock’s 14-day RSI is 64.81 (firm momentum), while the ATR of 0.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.68% below its high and over 26.56% above its low. Average 10-day trading volume of 2.48 million shares is in line with the 3-month average of 2.76 million, indicating normal recent market interest.

Summit Therapeutics Inc. has 742.85 million shares outstanding. The public float is 116.18 million shares, elevated short interest at 25.52% of float. This equals 29.81 million shares. The short ratio is 10.5 days. Institutional investors hold 103.03% of the float. Insiders own 86.05%. Xia Yu holds 32.06 million shares, Soni Manmeet Singh has 2.98 million shares and Zanganeh Maky has 359.97 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Summit Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

Summit Therapeutics Inc. generated EPS of -$1.24 over the past year. Five-year average earnings growth is -10.52%. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 16 Buy ratings, 2 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $50.00 to $13.00. The high target offers 154.07% upside. The low target suggests -33.94% downside. The mean target is $37.35. This offers 89.79% upside. Summit Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended October 20, 2025, missed forecasts by 121.43%. The prior quarter beat by 736.91%. Over the last six quarters, Apple has recorded several small beats. These include 79.95% in August 06, 2024.

Summit Therapeutics Inc. (NASDAQ:SMMT) closed at $19.68 USD, gaining $0.85 (4.51%) from the previous close of $18.83. The stock is currently mid-range between its 52-week high and low $15.55 and $36.91. With a market capitalization of about $14.65 billion, Summit Therapeutics Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~-1.51). Key stats such as the average daily volume over the past year has been around 2.83 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Summit Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert W. Duggan, the company employs approximately 159 people and listed since March 05, 2015. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.

Summit Therapeutics Inc. trades at a P/E ratio of -15.87, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 76.1 reflecting a rich premium to book value. The P/FCF stands at -53.84, also below market averages. Compared to sector medians, Summit Therapeutics Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Summit Therapeutics Inc. (NASDAQ:SMMT) shares are flat 7.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Summit Therapeutics Inc. trading at a premium to the broader market with a P/E of -15.87. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $32.78, suggesting 66.57% upside. Our AI forecast model points to short-term weakness (-1.42% over two weeks), a medium-term fall (-57.52% over three months), and a longer-term gain (33.38% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Summit Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.42%, with price expected at $19.40 by January 23, 2026, within a range of $18.69 to $20.11 3-Month Outlook: Projected fall of -57.52%, reaching $8.36 by April 09, 2026, with a range of $6.55 to $9.59. 1-Year Outlook: Projected gain of 33.38%, with price at $26.25 by December 31, 2026, within a range of $24.57 to $27.92.